493 related articles for article (PubMed ID: 29179585)
1. Immune-based strategies for mood disorders: facts and challenges.
Colpo GD; Leboyer M; Dantzer R; Trivedi MH; Teixeira AL
Expert Rev Neurother; 2018 Feb; 18(2):139-152. PubMed ID: 29179585
[TBL] [Abstract][Full Text] [Related]
2. Targeting the immune system in the treatment of bipolar disorder.
Rosenblat JD
Psychopharmacology (Berl); 2019 Oct; 236(10):2909-2921. PubMed ID: 30756134
[TBL] [Abstract][Full Text] [Related]
3. Immune response to stress induction as a predictor of cognitive-behavioral therapy outcomes in adolescent mood disorders: A pilot study.
Pearlstein JG; Staudenmaier PJ; West AE; Geraghty S; Cosgrove VE
J Psychiatr Res; 2020 Jan; 120():56-63. PubMed ID: 31634750
[TBL] [Abstract][Full Text] [Related]
4. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.
Bond DJ; Hadjipavlou G; Lam RW; McIntyre RS; Beaulieu S; Schaffer A; Weiss M;
Ann Clin Psychiatry; 2012 Feb; 24(1):23-37. PubMed ID: 22303520
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis.
Rosenblat JD; Kakar R; Berk M; Kessing LV; Vinberg M; Baune BT; Mansur RB; Brietzke E; Goldstein BI; McIntyre RS
Bipolar Disord; 2016 Mar; 18(2):89-101. PubMed ID: 26990051
[TBL] [Abstract][Full Text] [Related]
6. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders.
Schaffer A; McIntosh D; Goldstein BI; Rector NA; McIntyre RS; Beaulieu S; Swinson R; Yatham LN;
Ann Clin Psychiatry; 2012 Feb; 24(1):6-22. PubMed ID: 22303519
[TBL] [Abstract][Full Text] [Related]
7. Mitigation of Inflammation-Induced Mood Dysregulation by Long-Chain Omega-3 Fatty Acids.
McNamara RK
J Am Coll Nutr; 2015; 34 Suppl 1(0 1):48-55. PubMed ID: 26400435
[TBL] [Abstract][Full Text] [Related]
8. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
McNamara RK; Lotrich FE
Expert Rev Neurother; 2012 Sep; 12(9):1143-61. PubMed ID: 23039393
[TBL] [Abstract][Full Text] [Related]
9. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder.
Khairova RA; Machado-Vieira R; Du J; Manji HK
Int J Neuropsychopharmacol; 2009 May; 12(4):561-78. PubMed ID: 19224657
[TBL] [Abstract][Full Text] [Related]
10. The Promise and Limitations of Anti-Inflammatory Agents for the Treatment of Major Depressive Disorder.
Raison CL
Curr Top Behav Neurosci; 2017; 31():287-302. PubMed ID: 27278642
[TBL] [Abstract][Full Text] [Related]
11. Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics.
Vazquez GH; Camino S; Tondo L; Baldessarini RJ
CNS Neurol Disord Drug Targets; 2017; 16(8):858-869. PubMed ID: 28758582
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of anti-inflammatory treatment interventions on depression in individuals with major depressive disorder and high levels of inflammation: A systematic review of randomized clinical trials.
Allison DJ; Sharma B; Timmons BW
Physiol Behav; 2019 Aug; 207():104-112. PubMed ID: 31078670
[TBL] [Abstract][Full Text] [Related]
13. RNA therapeutics for mood disorders: current evidence toward clinical trials.
Le Marois M; Tzavara E; Ibrahim EC; Blin O; Belzeaux R
Expert Opin Investig Drugs; 2021 Jul; 30(7):721-736. PubMed ID: 33966550
[TBL] [Abstract][Full Text] [Related]
14. Role of neuro-immunological factors in the pathophysiology of mood disorders.
Bhattacharya A; Derecki NC; Lovenberg TW; Drevets WC
Psychopharmacology (Berl); 2016 May; 233(9):1623-36. PubMed ID: 26803500
[TBL] [Abstract][Full Text] [Related]
15. Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012.
Kanba S; Kato T; Terao T; Yamada K;
Psychiatry Clin Neurosci; 2013 Jul; 67(5):285-300. PubMed ID: 23773266
[TBL] [Abstract][Full Text] [Related]
16. Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease.
Zuzarte P; Duong A; Figueira ML; Costa-Vitali A; Scola G
Curr Drug Metab; 2018; 19(8):674-687. PubMed ID: 29512447
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Drugs for Mood Disorders.
Peedicayil J; Kumar A
Prog Mol Biol Transl Sci; 2018; 157():151-174. PubMed ID: 29933949
[TBL] [Abstract][Full Text] [Related]
18. Statins: Neurobiological underpinnings and mechanisms in mood disorders.
Walker AJ; Kim Y; Borissiouk I; Rehder R; Dodd S; Morris G; Nierenberg AA; Maes M; Fernandes BS; Dean OM; Williams LJ; Eyre HA; Kim SW; Zoungas S; Carvalho AF; Berk M
Neurosci Biobehav Rev; 2021 Sep; 128():693-708. PubMed ID: 34265321
[TBL] [Abstract][Full Text] [Related]
19. Advances in the gut microbiome and mood disorders.
Mörkl S; Butler MI; Lackner S
Curr Opin Psychiatry; 2023 Jan; 36(1):1-7. PubMed ID: 36131643
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis.
Husain MI; Strawbridge R; Stokes PR; Young AH
J Psychopharmacol; 2017 Sep; 31(9):1137-1148. PubMed ID: 28858537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
